$24.58
+3.9%Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Executive Vice President & Chief Financial Officer
Executive Vice President & Chief Financial Officer
Compensation
$1,294,327
Executive Vice President & President of Elanco International
Compensation
$1,127,451
Executive Vice President of Corporate Strategy & Market Development
Compensation
$1,133,353
Executive Vice President of Human Resources, Corporate Communications & Administration
Compensation
$722,576
Executive Vice President of Research, Development & Regulatory Affairs
Compensation
$1,371,893
Executive Vice President, General Counsel & Corporate Secretary
President, Chief Executive Officer & Director
Compensation
$2,833,671
Senior Vice President & Chief Accounting Officer
Senior Vice President & Chief Information Officer
Senior Vice President of Asia
Vice President of Investor Relations & ESG
During the last 12 months, insiders have purchased $1.14M worth of ELAN shares, with no selling activity reported.
9.9K
199.78K
0
0.00
+200K
+$200K
43.5K
937.90K
0
0.00
+938K
+$938K
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
Simmons Jeffrey N
Director, Officer: President, Ceo And Director
$578K
Kurzius Lawrence Erik
Director
$213K
Modi Rajeev A.
Officer: See Remarks
$196K
Vanhimbergen Robert M
Officer: Evp And Cfo
$150K
No selling activity
Strong bullish signal with $1.14M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
4 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
ELAN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 08, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | March 27, 2025 | May 16, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 19, 2024 | May 30, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 06, 2023 | April 06, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 06, 2022 | May 18, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | March 25, 2021 | May 19, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 08, 2020 | May 21, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 03, 2019 | May 08, 2019 | 2019 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.